171 related articles for article (PubMed ID: 37861957)
21. Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 Inhibitors.
Frost DA; Soric MM; Kaiser R; Neugebauer RE
Pharmacotherapy; 2019 Jun; 39(6):724-729. PubMed ID: 31038218
[TBL] [Abstract][Full Text] [Related]
22. Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.
Paulzen M; Haen E; Hiemke C; Stegmann B; Lammertz SE; Gründer G; Schoretsanitis G
Br J Clin Pharmacol; 2017 Aug; 83(8):1668-1675. PubMed ID: 28160505
[TBL] [Abstract][Full Text] [Related]
23. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
[TBL] [Abstract][Full Text] [Related]
24. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
25. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.
Stamer UM; Zhang L; Book M; Lehmann LE; Stuber F; Musshoff F
PLoS One; 2013; 8(3):e60239. PubMed ID: 23555934
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
[TBL] [Abstract][Full Text] [Related]
27. A Multicenter Retrospective Observational Study Analyzing the Effect of Polypharmacy on Oxycodone Tolerability.
Makihara K; Yamamoto Y; Miyazaki M; Taguchi M; Sato J; Takase H; Uezono Y
J Pain Palliat Care Pharmacother; 2024 Mar; 38(1):3-12. PubMed ID: 38227839
[TBL] [Abstract][Full Text] [Related]
28. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.
de Leon J; Dinsmore L; Wedlund P
J Clin Psychopharmacol; 2003 Aug; 23(4):420-1. PubMed ID: 12920424
[No Abstract] [Full Text] [Related]
29. In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2013 Oct; 37(8):476-85. PubMed ID: 23857299
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenomics of oxycodone: a narrative literature review.
Umukoro NN; Aruldhas BW; Rossos R; Pawale D; Renschler JS; Sadhasivam S
Pharmacogenomics; 2021 Apr; 22(5):275-290. PubMed ID: 33728947
[TBL] [Abstract][Full Text] [Related]
31. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.
Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH
Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813
[TBL] [Abstract][Full Text] [Related]
32. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Heiskanen T; Olkkola KT; Kalso E
Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
[TBL] [Abstract][Full Text] [Related]
33. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
34. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.
Zakrzewski-Jakubiak H; Doan J; Lamoureux P; Singh D; Turgeon J; Tannenbaum C
Am J Geriatr Pharmacother; 2011 Dec; 9(6):461-70. PubMed ID: 22019006
[TBL] [Abstract][Full Text] [Related]
35. Commonly Initiated Opioids and Risk of Fracture Hospitalizations in United States Nursing Homes.
Hunnicutt JN; Hume AL; Liu SH; Ulbricht CM; Tjia J; Lapane KL
Drugs Aging; 2018 Oct; 35(10):925-936. PubMed ID: 30187291
[TBL] [Abstract][Full Text] [Related]
36. Opioid pharmacokinetic drug-drug interactions.
Overholser BR; Foster DR
Am J Manag Care; 2011 Sep; 17 Suppl 11():S276-87. PubMed ID: 21999760
[TBL] [Abstract][Full Text] [Related]
37. Correlation between gene polymorphism and opioid efficacy in patients with gastric or intestinal cancer.
Pu J; Wang N; Huang ZK; He XY; Yuan HB
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9393-9410. PubMed ID: 31773688
[TBL] [Abstract][Full Text] [Related]
38. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards.
Davies SJ; Eayrs S; Pratt P; Lennard MS
Br J Clin Pharmacol; 2004 Apr; 57(4):464-72. PubMed ID: 15025745
[TBL] [Abstract][Full Text] [Related]
39. Gender difference in prescription opioid abuse: A focus on oxycodone and hydrocodone.
Graziani M; Nisticò R
Pharmacol Res; 2016 Jun; 108():31-38. PubMed ID: 27107788
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases.
Jannetto PJ; Wong SH; Gock SB; Laleli-Sahin E; Schur BC; Jentzen JM
J Anal Toxicol; 2002 Oct; 26(7):438-47. PubMed ID: 12422998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
